Inotersen
An article about the medication Inotersen
Inotersen is a medication used in the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. It is an antisense oligonucleotide that targets the transthyretin (TTR) protein, reducing its production and thereby alleviating the symptoms associated with the disease.
Mechanism of Action[edit | edit source]
Inotersen works by binding to the messenger RNA (mRNA) of the transthyretin protein, which is primarily produced in the liver. By binding to the mRNA, inotersen prevents the translation of the TTR protein, leading to a decrease in its levels in the bloodstream. This reduction in TTR protein helps to prevent the formation of amyloid deposits in tissues, which are responsible for the symptoms of hATTR.
Clinical Use[edit | edit source]
Inotersen is indicated for the treatment of adults with hereditary transthyretin-mediated amyloidosis. This condition is characterized by the accumulation of amyloid fibrils in various organs and tissues, leading to a range of symptoms including peripheral neuropathy, autonomic dysfunction, and cardiomyopathy.
Administration[edit | edit source]
Inotersen is administered via subcutaneous injection. The typical dosing regimen involves weekly injections, which patients can self-administer after receiving appropriate training.
Side Effects[edit | edit source]
Common side effects of inotersen include injection site reactions, nausea, headache, and fatigue. More serious side effects can include thrombocytopenia (low platelet count) and glomerulonephritis (inflammation of the kidneys). Regular monitoring of platelet counts and renal function is recommended during treatment.
Monitoring[edit | edit source]
Patients receiving inotersen require regular monitoring to ensure safety and efficacy. This includes:
- Regular platelet count checks to monitor for thrombocytopenia.
- Renal function tests to detect any signs of kidney damage.
- Liver function tests, as the liver is the primary site of TTR production.
Related pages[edit | edit source]
Inotersen
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju, Prab R. Tumpati, MD
